g****e
发帖数: 1426 | 1 Just found that the reason:
20 min shares sell by the company
Go to investorshub for the detailes.
Hope it helpful. | S*********g
发帖数: 52 | 2 by the company? What company? Horizan itself?!
【在 g****e 的大作中提到】
: Just found that the reason:
: 20 min shares sell by the company
: Go to investorshub for the detailes.
: Hope it helpful.
| g****e
发帖数: 1426 | 3 Please see dilution:
http://ih.advfn.com/p.php?pid=nmona&article=53612982
This Prospectus Supplement No. 4 supplements and amends the prospectus dated
May 2, 2012, or the Original Prospectus, and the other Prospectus
Supplements thereto, dated May 10, 2012, June 11, 2012 and June 19, 2012,
which we refer to collectively as the Prospectus. The Prospectus relates to
the sale of an aggregate of 20,819,468 shares of our common stock, $0.0001
par value per share, by the selling stockholders identified in the Original
Prospectus, including their transferees, pledgees, donees or successors.
On July 26, 2012, we filed with the Securities and Exchange Commission a
Current Report on Form 8-K relating to the approval of RAYOS ® by the U.
S. Food and Drug Administration. The information set forth below supplements
and amends the information contained in the Prospectus. This Prospectus
Supplement No. 4 should be read in conjunction with, and delivered with, the
Prospectus and is qualified by reference to the Prospectus except to the
extent that the information in this Prospectus Supplement No. 4 supersedes
the information contained in the Prospectus.
The selling stockholders may sell their shares of common stock from time to
time at market prices prevailing at the time of sale, at prices related to
the prevailing market price, or at negotiated prices. We will not receive
any proceeds from the sale of common stock by the selling stockholders,
other than as a result of the exercise of warrants held by the selling
stockholders for cash.
No underwriter or other person has been engaged to facilitate the sale of
shares of our common stock in this offering. We have paid the cost of
registering the shares of common stock covered by the Prospectus as well as
various related expenses. The selling stockholders are responsible for all
selling commissions, transfer taxes and other costs related to the offer and
sale of their shares of common stock.
Our common stock is traded on The NASDAQ Global Market under the symbol “
HZNP.” On July 24, 2012, the closing sale price of our common stock on The
NASDAQ Global Market was $7.56 per share. | s*******n
发帖数: 347 | | n******0
发帖数: 298 | 5 What about AMRN selling off? | g****e
发帖数: 1426 | 6 Investors expect NCE news along with approval of vascepa(the management said
could be together). I don't think the labeling caused the sell off of AMRN,
the label is expected to be based on MARIN clinical studies, Anchor studies
will be included on label by sNDA which should be a standard process. Just
my 2 cents. | n******0
发帖数: 298 | 7 What is your sugession about this stock, hold or sell?
said
AMRN,
studies
Just
【在 g****e 的大作中提到】
: Investors expect NCE news along with approval of vascepa(the management said
: could be together). I don't think the labeling caused the sell off of AMRN,
: the label is expected to be based on MARIN clinical studies, Anchor studies
: will be included on label by sNDA which should be a standard process. Just
: my 2 cents.
| g****e
发帖数: 1426 | 8 See my thoughts(buy, sell or hold) on HZNP and AMRN in my precious poster --
- Biotech discussion group. Do your own DD. Good luck!! |
|
